AGTC A3

Actively Recruiting // Clinical Trials // Inherited Retinal Degeneration // Kimberly Stepien // Sep 30 2020

A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC-402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients with Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene (AGTC A3)

  • Sponsor: Applied Genetic Technologies Corporation
  • Principal Investigator: Kimberly Stepien, MD
  • Study Coordinator: Nickie Stangel

Study objective:

This study will evaluate the safety and efficacy of AGTC-402 in patients with congenital achromatopsia caused by mutations in the CNGA3 gene

Study design:

Study participants will be enrolled into 6 non-randomized groups. Each participant will receive AGTC-402 in a volume of up to 0.30 mL administered by subretinal injection in one eye on a single occasion during the study.

Diagnosis and Key Eligibility Criteria:

Male or females with documented mutations in both alleles of the CNGA3 gene with confirmation by segregation analysis for subjects with compound heterozygous mutations wherever possible, and retinal disease consistent with a clinical diagnosis of achromatopsia. Ages ≥18 years for groups 1-5 and ≥6 for groups 3a, 4a, and 6. Prior use of any AAV gene therapy product is not allowed

Duration of study: Approximately 5 years

For more information, contact Nickie Stangel 608-263-8783